+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-01-27Number of Pages: 128

Platelet Rich Plasma Market (By Type: Pure PRP, Leucocytes and PRP, Platelet Rich Fibrin; By Origin: Autologous PRP, Allogeneic PRP, and Homologous PRP; By Application: Orthopedic Surgery, Cosmetic Surgery, General Surgery, Neurosurgery, and Other Surgeries) - Asia Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

This report provides a comprehensive analysis of the platelet rich plasma market in Asia Pacific considering various macro as well as microeconomic factors such as regulations, applications of platelet rich plasma, and advantages and disadvantages of type of platelet rich plasma, and cost. The report studies the platelet rich plasma market from four perspectives: type of platelet rich plasma, origin of platelet rich plasma, application of platelet rich plasma, and country wise market.  

Based on the type of platelet rich plasma, the market in Asia Pacific has been segmented into pure platelet rich plasma, leucocytes and platelet rich plasma, and platelet rich fibrin. Based on origin, the market has been segmented into autologous platelet rich plasma, allogeneic platelet rich plasma, and homologous platelet rich plasma. In terms of the application of platelet rich plasma, the market has been segmented into orthopedic surgery, cosmetic surgery, general surgery, neurosurgery, and other surgeries. In terms of country, the market has been studied for eleven major geographies: Australia, the Philippines, China, India, Singapore, Thailand, Malaysia, South Korea, Hong Kong, Taiwan, and Rest of Asia Pacific. Additionally, each segment of the platelet rich plasma market has been further subdivided into national markets. 

The market size for each of the segments and sub-segments mentioned above is provided in US$ Mn considering 2013 and 2014 as base years and forecast from 2015 to 2023. The forecast model considers various factors such as number of surgeries, health care expenditure of the country, advantages of the individual segment, penetration of platelet rich plasma therapy in the country, the cost of platelet rich plasma in various countries, and government regulations. The research methodology is a blend of primary as well as secondary market research, where market estimates based on desk research are further refined considering inputs from expert interviews.

This report on the platelet rich plasma market in Asia Pacific also provides qualitative information on major players in the market. It also includes details on current regulatory policies for platelet rich plasma and devices. Major factors driving and restraining the platelet rich plasma market are also discussed in the report, while opportunities from the future perspective are also mentioned. Furthermore, the platelet rich plasma market report provides value chain analysis for comprehensive analysis. Porter’s Five Forces Analysis will provide the idea of bargaining power of buyers, bargaining power of suppliers, threat of new entrants in platelet rich plasma market, threat of substitutes, and competitive rivalry in platelet rich plasma market. Additionally, market share analysis of the platelet rich plasma market in Asia Pacific provides detailed information on current competitive landscape of the market. Market attractiveness analysis provides information on most attractive countries for platelet rich plasma.   

Finally, the report profiles major players in the platelet rich plasma market in Asia Pacific including Harvest Technology, Arthrex, Inc., Stryker Corporation, Zimmer Biomet, DePuy Synthes, AdiStem Ltd., Cesca Therapeutics, Inc., Exactech, Inc., and Rmedica Co. Ltd. Each of the companies is profiled for parameters such as company overview, financial overview, product portfolio, business strategies, and recent developments. The report on the platelet rich plasma market estimation and forecast comprises 128 slides and 68 graphs. 


1. Introduction  
    1.1 Report Description
    1.2 Research Methodology
    1.3 Market Segmentation

2. Executive Summary
    2.1 Market Snapshot

3. Asia Pacific Platelet Rich Plasma Market Overview
    3.1 Introduction
    3.2 Value Chain Analysis
    3.3 Regulatory Framework
    3.4 Market Dynamics
         3.4.1 Drivers
         3.4.2 Restraints
         3.4.3 Opportunities
    3.5 Porter’s Five Force Analysis
         3.5.1 Bargaining Power of Buyers
         3.5.2 Bargaining Power of Suppliers
         3.5.3 Threat of New Entrants
         3.5.4 Threat of Substitutes
         3.5.5 Competitive Rivalry
    3.6 Market Attractiveness Analysis of the Asia Pacific Platelet Rich Plasma Market, by Country, 2014
    3.7 Competitive Landscape: Market Share Analysis by Key Players, 2014 (Value, %)

4. Asia Pacific Platelet Rich Plasma Market Revenue, by Type, 2013–2023 (US$ Mn)
    4.1 Overview
    4.2 Pure Platelet-Rich Plasma (P-PRP) Market Revenue, by Country, 2013–2023 (US$ Mn)
         4.2.1 Australia
         4.2.2 Philippines
         4.2.3 China
         4.2.4 India
         4.2.5 Singapore
         4.2.6 Thailand
         4.2.7 Malaysia
         4.2.8 Korea
         4.2.9 Hong Kong
         4.2.10 Taiwan
         4.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
    4.3 Leukocyte-Rich Platelet-Rich Plasma (L-PRP)*
    4.4 Pure Platelet-Rich Fibrin (P-PRF)/ Leukocyte-Rich Platelet-Rich Fibrin (L-PRF)*

5. Asia Pacific Platelet Rich Plasma Market Revenue, by Origin, 2013–2023 (US$ Mn)
    5.1 Overview
    5.2 Autologous Platelet-Rich Plasma
         5.2.1 Australia
         5.2.2 Philippines
         5.2.3 China
         5.2.4 India
         5.2.5 Singapore
         5.2.6 Thailand
         5.2.7 Malaysia
         5.2.8 Korea
         5.2.9 Hong Kong
         5.2.10 Taiwan
         5.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
    5.3 Allogeneic Platelet-Rich Plasma*
    5.4 Homologous Platelet-Rich Plasma*

6. Asia Pacific Platelet Rich Plasma Market Revenue, by Application, 2013–2023 (US$ Mn)
    6.1 Overview
    6.2 Orthopedic Surgery
         6.2.1 Australia
         6.2.2 Philippines
         6.2.3 China
         6.2.4 India
         6.2.5 Singapore
         6.2.6 Thailand
         6.2.7 Malaysia
         6.2.8 Korea
         6.2.9 Hong Kong
         6.2.10 Taiwan
         6.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
    6.3 Cosmetic Surgery*
    6.4 General Surgery*
    6.5 Neurosurgery*
    6.6 Other Surgeries (Urology, Cardiothoracic, Oral & Maxillofacial and Periodontal)*

7. Asia Pacific Platelet Rich Plasma Market Revenue, by Country, 2013–2023 (US$ Mn)
    7.1 Overview
    7.2 Australia
    7.3 Philippines
    7.4 China
    7.5 India
    7.6 Singapore
    7.7 Thailand
    7.8 Malaysia
    7.9 Korea
    7.10 Hong Kong
    7.11 Taiwan
    7.12 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)

8. Recommendations

9. Company Profiles
    9.1 AdiStem Ltd.
    9.2 Arthrex, Inc.
    9.3 Biomet, Inc.
    9.4 Cesca Therapeutics, Inc.
    9.5 DePuy Synthes, Inc.
    9.6 Exactech, Inc.
    9.7 Harvest Technologies Corp.
    9.8 NeoGenesis Co. Ltd.
    9.9 Rmedica Co. Ltd.
    9.10 Stryker Corporation
    9.11 Seawon Meditech
    9.12 Others

*: Similar country wise analysis provided for all other segments

Platelet rich plasma (PRP) is patient’s own blood plasma or donor’s blood plasma used to stimulate regeneration and repairing of soft tissue and bones. PRP contains four to eight times more platelet concentration than individual blood plasma. Platelets play a major role in blood clotting. These also contain hundreds of proteins called growth factors such as platelet-derived growth factor, transforming growth factor-ß, platelet-derived epidermal growth factor, vascular endothelial growth factor, insulin-like growth factor-1, fibroblastic growth factor, and epidermal growth factor that are important in healing injuries.

Advances in platelet rich plasma devices due to increasing research has resulted in rapid growth in demand for PRP therapy. Additionally, increasing prevalence of orthopedic disorders and sports injuries, growing application in plastic or cosmetic surgeries, and rising awareness about PRP efficacy have fueled the growth of the market in Asia Pacific. The region currently accounts for a small share of the global platelet rich plasma market. However, advances in PRP and PRF research, widespread use of PRP, and medical tourism are expected to accelerate the growth of the market in Asia Pacific.

The PRP market in Asia Pacific has been segmented based on type, origin, and application of PRP. Based on type, the market has been further segmented into pure PRP, leucocytes and PRP, and platelet rich fibrin. Pure PRP dominated the PRP market in Asia Pacific in 2014 due to high concentration of platelets, less contamination, and low cost as compared to other PRP products. However, platelet rich fibrin, an advanced form of PRP, is likely to witness the fastest growth during the forecast period from 2015 to 2023 due to faster recovery (because of high content of growth factors) and sustained release of growth factors. Based on origin, the market has been segmented into autologous PRP, allogeneic PRP, and homologous PRP. Presently, the autologous PRP segment dominates the PRP market in Asia Pacific due to no risk of infection and allergic reaction and low cost. Homologous PRP accounts for minor share of the PRP market due to limited commercial application in human beings and high cost as compared to autologous PRP. Based on application, the PRP market in Asia Pacific has been divided into orthopedic surgery, cosmetic surgery, general surgery, neurosurgery, and other surgeries. The orthopedic surgeries application segment accounted for the largest share of the market in 2014 due to increasing geriatric population and growing sports injuries and road accidents. However, the cosmetic surgery segment is likely to expand at the fastest rate during forecast period due to increasing awareness and noninvasive nature of surgery.

Geographically, the PRP market in Asia Pacific has been segmented into Australia, Philippines, China, India, Singapore, Thailand, Malaysia, South Korea, Taiwan, Hong Kong, and Rest of Asia Pacific. Presently, China dominates the PRP market in the region and is likely to continue its dominance during the forecast period from 2015 to 2023. Significant investment in PRP research, increasing demand for PRP due to growing awareness, and minimum regulations for approval of devices are the major drivers of the PRP market in China.

Key players in the market include Harvest Technology, Arthrex, Inc., Stryker Corporation, Zimmer Biomet, DePuy Synthes, AdiStem Ltd., Cesca Therapeutics, Inc., Exactech, Inc., and Rmedica Co. Ltd.

 

asia-pacific-platelet-rich-plasma-market

 


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries